1. Home
  2. FCEL vs MREO Comparison

FCEL vs MREO Comparison

Compare FCEL & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FuelCell Energy Inc.

FCEL

FuelCell Energy Inc.

HOLD

Current Price

$6.63

Market Cap

370.1M

Sector

Energy

ML Signal

HOLD

Logo Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc

HOLD

Current Price

$0.39

Market Cap

67.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCEL
MREO
Founded
1969
2015
Country
United States
United Kingdom
Employees
629
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
370.1M
67.5M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
FCEL
MREO
Price
$6.63
$0.39
Analyst Decision
Hold
Buy
Analyst Count
4
6
Target Price
$8.31
$3.90
AVG Volume (30 Days)
1.2M
1.9M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.91
N/A
Revenue Next Year
$35.84
$6,363.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.58
$0.20
52 Week High
$11.99
$2.94

Technical Indicators

Market Signals
Indicator
FCEL
MREO
Relative Strength Index (RSI) 38.96 39.30
Support Level $6.35 $0.35
Resistance Level $10.69 $0.45
Average True Range (ATR) 0.65 0.03
MACD -0.15 0.02
Stochastic Oscillator 1.80 53.37

Price Performance

Historical Comparison
FCEL
MREO

About FCEL FuelCell Energy Inc.

FuelCell Energy Inc is a clean energy technology company engaged in the development, design, production, and servicing of high temperature fuel cells for clean electric power generation. The Company provides proprietary molten carbonate fuel cell systems that generate electricity electrochemically with ultra low emissions and high efficiency, and operates as a solutions provider managing the design, manufacturing, installation, and maintenance of its systems under long term power purchase, service, and engineering procurement agreements. The Company serves utilities, data centers, and commercial and industrial customers, and operates in the United States, South Korea, Europe, and Canada, with maximum revenue generated from the United States.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: